Inhibitory effect of human TRIM5α on HIV-1 production

Microbes and Infection

Volumn 12, Issue 10, 2010, Pages 768-777

  Zhang, Xianfeng ^a   Kondo, Mariko ^a   Chen, Jing ^a   Miyoshi, Hiroyuki ^b   Suzuki, Hajime ^a   Ohashi, Takashi ^a   Shida, Hisatoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b RIKEN BIORESOURCE CENTER   (Japan)

Author keywords

HIV 1 production; Human TRIM5 ; Intrinsic immunity; MLV; Restriction factor

Indexed keywords

ARGININE; COMPLEMENTARY DNA; CYSTEINE; GAG PROTEIN; MESSENGER RNA; SMALL INTERFERING RNA; TRIPARTITE MOTIF PROTEIN 5;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOBLOTTING; LEUKEMIA VIRUS; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; SPECIES DIFFERENCE; TRANSIENT EXPRESSION; VIRION; VIRUS CONCENTRATION; VIRUS ENTRY; VIRUS INHIBITION; VIRUS LIKE AGENT; VIRUS RESISTANCE; WESTERN BLOTTING;

AMINO ACID SUBSTITUTION; ANIMALS; CARRIER PROTEINS; CELLS, CULTURED; GENE KNOCKDOWN TECHNIQUES; HIV-1; HUMANS; MACACA MULATTA;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; MURINE LEUKEMIA VIRUS;

EID: 77956263295     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2010.05.004     Document Type: Article

References (47)

1. Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646-650.
2. Wiegand H.L., Doehle B.P., Bogerd H.P., Cullen B.R. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 2004, 23:2451-2458.
3. Takaori-Kondo A. APOBEC family proteins: novel antiviral innate immunity. Int. J. Hematol. 2006, 83:213-216.
4. Goila-Gaur R., Strebel K. HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 2008, 5:51.
5. Neil S.J., Zang T., Bieniasz P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451:425-430.
6. Bieniasz P.D. Intrinsic immunity: a front-line defense against viral attack. Nat. Immunol. 2004, 5:1109-1115.
7. Emerman M. How TRIM5alpha defends against retroviral invasions. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:5249-5250.
8. Sakuma R., Mael A.A., Ikeda Y. Alpha interferon enhances TRIM5alpha-mediated antiviral activities in human and rhesus monkey cells. J. Virol. 2007, 81:10201-10206.
9. Peng G., Lei K.J., Jin W., Greenwell-Wild T., Wahl S.M. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J. Exp. Med. 2006, 203:41-46.
10. Perron M.J., Stremlau M., Lee M., Javanbakht H., Song B., Sodroski J. The human TRIM5alpha restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid. J. Virol. 2007, 81:2138-2148.
11. Stremlau M., Perron M., Lee M., Li Y., Song B., Javanbakht H., Diaz-Griffero F., Anderson D.J., Sundquist W.I., Sodroski J. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:5514-5519.
12. Perez-Caballero D., Hatziioannou T., Zhang F., Cowan S., Bieniasz P.D. Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. J. Virol. 2005, 79:15567-15572.
13. Perez-Caballero D., Hatziioannou T., Yang A., Cowan S., Bieniasz P.D. Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J. Virol. 2005, 79:8969-8978.
14. Hatziioannou T., Perez-Caballero D., Cowan S., Bieniasz P.D. Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. J. Virol. 2005, 79:176-183.
15. Berthoux L., Sebastian S., Sokolskaja E., Luban J. Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA. J. Virol. 2004, 78:11739-11750.
16. Wu X., Anderson J.L., Campbell E.M., Joseph A.M., Hope T.J. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:7465-7470.
17. Sakuma R., Noser J.A., Ohmine S., Ikeda Y. Rhesus monkey TRIM5alpha restricts HIV-1 production through rapid degradation of viral Gag polyproteins. Nat. Med. 2007, 13:631-635.
18. Zhang F., Perez-Caballero D., Hatziioannou T., Bieniasz P.D. No effect of endogenous TRIM5alpha on HIV-1 production. Nat. Med. 2008, 14:235-236. (author reply 236-238).
19. Stremlau M., Perron M., Welikala S., Sodroski J. Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J. Virol. 2005, 79:3139-3145.
20. Song B., Gold B., O'Huigin C., Javanbakht H., Li X., Stremlau M., Winkler C., Dean M., Sodroski J. The B30.2(SPRY) domain of the retroviral restriction factor TRIM5alpha exhibits lineage-specific length and sequence variation in primates. J. Virol. 2005, 9:6111-6121.
21. Sakuma R., Ohmine S., Ikeda Y. Determinants for the rhesus monkey TRIM5{alpha}-mediated block of the late phase of HIV-1 replication. J. Biol. Chem. 2009.
22. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents. Chemother. 2002, 46:1896-1905.
23. Morita S., Kojima T., Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene. Ther. 2000, 7:1063-1066.
24. Onishi M., Nosaka T., Misawa K., Mui A.L., Gorman D., McMahon M., Miyajima A., Kitamura T. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol. Cell Biol. 1998, 18:3871-3879.
25. Iwakura Y., Shioda T., Tosu M., Yoshida E., Hayashi M., Nagata T., Shibuta H. The induction of cataracts by HIV-1 in transgenic mice. AIDS 1992, 6:1069-1075.
26. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., Martin M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 1986, 59:284-291.
27. Koyanagi Y., Miles S., Mitsuyasu R.T., Merrill J.E., Vinters H.V., Chen I.S. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 1987, 236:819-822.
28. Kestler H., Kodama T., Ringler D., Marthas M., Pedersen N., Lackner A., Regier D., Sehgal P., Daniel M., King N., et al. Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science 1990, 248:1109-1112.
29. Shibata R., Miura T., Hayami M., Sakai H., Ogawa K., Kiyomasu T., Ishimoto A., Adachi A. Construction and characterization of an infectious DNA clone and of mutants of simian immunodeficiency virus isolated from the African green monkey. J. Virol. 1990, 64:307-312.
30. Peden K., Emerman M., Montagnier L. Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology 1991, 185:661-672.
31. Katahira J., Ishizaki T., Sakai H., Adachi A., Yamamoto K., Shida H. Effects of translation initiation factor eIF-5A on the functioning of human T-cell leukemia virus type I Rex and human immunodeficiency virus Rev inhibited trans dominantly by a Rex mutant deficient in RNA binding. J. Virol. 1995, 69:3125-3133.
32. Tahara-Hanaoka S., Sudo K., Ema H., Miyoshi H., Nakauchi H. Lentiviral vector-mediated transduction of murine CD34(-) hematopoietic stem cells. Exp. Hematol. 2002, 30:11-17.
33. Bock M., Bishop K.N., Towers G., Stoye J.P. Use of a transient assay for studying the genetic determinants of Fv1 restriction. J. Virol. 2000, 74:7422-7430.
34. Ikuta K., Morita C., Miyake S., Ito T., Okabayashi M., Sano K., Nakai M., Hirai K., Kato S. Expression of human immunodeficiency virus type 1 (HIV-1) gag antigens on the surface of a cell line persistently infected with HIV-1 that highly expresses HIV-1 antigens. Virology 1989, 170:408-417.
35. Li X., Li Y., Stremlau M., Yuan W., Song B., Perron M., Sodroski J. Functional replacement of the RING, B-box 2, and coiled-coil domains of tripartite motif 5alpha (TRIM5alpha) by heterologous TRIM domains. J. Virol. 2006, 80:6198-6206.
36. Keckesova Z., Ylinen L.M., Towers G.J. The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:10780-10785.
37. Perron M.J., Stremlau M., Song B., Ulm W., Mulligan R.C., Sodroski J. TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:11827-11832.
38. Yap M.W., Nisole S., Lynch C., Stoye J.P. Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:10786-10791.
39. Yap M.W., Nisole S., Stoye J.P. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr. Biol. 2005, 15:73-78.
40. Li Y., Li X., Stremlau M., Lee M., Sodroski J. Removal of arginine 332 allows human TRIM5alpha to bind human immunodeficiency virus capsids and to restrict infection. J. Virol. 2006, 80:6738-6744.
41. Diaz-Griffero F., Perron M., McGee-Estrada K., Hanna R., Maillard P.V., Trono D., Sodroski J. A human TRIM5alpha B30.2/SPRY domain mutant gains the ability to restrict and prematurely uncoat B-tropic murine leukemia virus. Virology 2008, 378:233-242.
42. Maillard P.V., Reynard S., Serhan F., Turelli P., Trono D. Interfering residues narrow the spectrum of MLV restriction by human TRIM5alpha. PLoS Pathog. 2007, 3:e200.
43. Speelmon E.C., Livingston-Rosanoff D., Li S.S., Vu Q., Bui J., Geraghty D.E., Zhao L.P., McElrath M.J. Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. J. Virol. 2006, 80:2463-2471.
44. Nakayama E.E., Carpentier W., Costagliola D., Shioda T., Iwamoto A., Debre P., Yoshimura K., Autran B., Matsushita S., Theodorou I. Wild type and H43Y variant of human TRIM5alpha show similar anti-human immunodeficiency virus type 1 activity both in vivo and in vitro. Immunogenetics 2007, 59:511-515.
45. van Manen D., Rits M.A., Beugeling C., van Dort K., Schuitemaker H., Kootstra N.A. The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog 2008, 4:e18.
46. Torimiro J.N., Javanbakht H., Diaz-Griffero F., Kim J., Carr J.K., Carrington M., Sawitzke J., Burke D.S., Wolfe N.D., Dean M., Sodroski J. A rare null allele potentially encoding a dominant-negative TRIM5alpha protein in Baka pygmies. Virology 2009, 391:140-147.
47. Carthagena L., Parise M.C., Ringeard M., Chelbi-Alix M.K., Hazan U., Nisole S. Implication of TRIM alpha and TRIMCyp in interferon-induced anti-retroviral restriction activities. Retrovirology 2008, 5:59.